Prognostic role of ABO blood type in patients with extranodal natural killer/T cell lymphoma, nasal type: a triple-center study

Table 4 Univariate and multivariate analysis of prognostic factors for PFS and OS in patients with ENKTL

Variable	PFS			OS
	Univariate analysis	Multivariate analysis		Univariate analysis	Multivariate analysis
	P	RR (95% CI)	P	P	RR (95% CI)	P
Age (>60 years vs. ≤60 years)	0.002	1.140 (0.886–1.467)	0.308	<0.001	1.904 (1.434–2.527)	<0.001
B symptoms (yes vs. no)	0.052	–	–	0.019	1.285 (0.981–1.685)	0.069
Tumor size ≥5 cm (yes vs. no)	<0.001	1.555 (1.130–2.139)	0.007	<0.001	1.720 (1.233–2.400)	0.001
Extranodal sites ≥2 (yes vs. no)	<0.001	0.974 (0.577–1.642)	0.920	<0.001	0.857 (0.491–1.496)	0.586
Regional LN involvement (yes vs. no)	<0.001	1.323 (1.041–1.680)	0.022	0.030	1.230 (0.898–1.686)	0.197
Stage III/IV (yes vs. no)	<0.001	1.142 (0.650–2.009)	0.644	<0.001	2.114 (1.554–2.875)	<0.001
LDH >245 U/L (yes vs. no)	<0.001	1.293 (0.937–1.783)	0.118	<0.001	1.514 (1.183–1.936)	0.001
Blood group non-O (yes vs. no)	<0.001	1.539 (1.266–1.932)	<0.001	0.001	1.491 (1.166–1.906)	0.001
IPI score ≥2 (yes vs. no)	<0.001	2.285 (1.751–2.983)	<0.001	<0.001	1.021 (0.570–1.828)	0.945
KPI score ≥2 (yes vs. no)	<0.001	0.970 (0.642–1.466)	0.886	<0.001	0.846 (0.539–1.327)	0.467

PFS progression-free survival, OS overall survival, RR relative risk, CI confidence interval, LN lymph node, LDH lactate dehydrogenase, IPI International Prognostic Index, KPI Korean Prognostic Index, – not assessed

ISSN: 2523-3548